| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1)：7-30.
|
| [2] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3)：209-249.
|
| [3] |
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406 (6797)：747-752.
|
| [4] |
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15 Pt 1)：4429-4434.
|
| [5] |
Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress[J]. Breast Cancer Res, 2020, 22(1)：61.
|
| [6] |
Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes[J]. J Pathol, 2014, 232(2)：142-150.
|
| [7] |
Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes[J]. Clin Cancer Res, 2013, 19(19)：5533-5540.
|
| [8] |
Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer[J]. Clin Cancer Res, 2015, 21(7)：1688-1698.
|
| [9] |
Jézéquel P, Loussouarn D, Guérin-Charbonnel C, et al. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response[J]. Breast Cancer Res, 2015, 17：43.
|
| [10] |
Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection[J]. PLoS One, 2016, 11(6)：e0157368.
|
| [11] |
Jiang YZ, Liu Y, Xiao Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial[J]. Cell Res, 2021, 31(2)：178-186.
|
| [12] |
Gong Y, Ji P, Yang YS, et al. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets[J]. Cell Metab, 2021, 33(1)：51-64.
|
| [13] |
Armstrong N, Ryder S, Forbes C, et al. A systematic review of the international prevalence of BRCA mutation in breast cancer[J]. Clin Epidemiol, 2019, 11：543-561.
|
| [14] |
da Silva JL, Cardoso Nunes NC, Izetti P, et al. Triple negative breast cancer: a thorough review of biomarkers[J]. Crit Rev Oncol Hematol, 2020, 145：102855.
|
| [15] |
Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer[J]. J Clin Oncol, 2015, 33(4)：304-311.
|
| [16] |
Sukumar J, Gast K, Quiroga D, et al. Triple-negative breast cancer: promising prognostic biomarkers currently in development[J]. Expert Rev Anticancer Ther, 2021, 21(2)：135-148.
|
| [17] |
Duffy MJ, Synnott NC, Crown J. Mutant p53 in breast cancer: potential as a therapeutic target and biomarker[J]. Breast Cancer Res Treat, 2018, 170(2): 213-219.
|
| [18] |
Martínez-Sáez O, Chic N, Pascual T, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer[J]. Breast Cancer Res, 2020, 22(1)：45.
|
| [19] |
Mosele F, Stefanovska B, Lusque A, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer[J]. Ann Oncol, 2020, 31(3)：377-386.
|
| [20] |
Loibl S, Poortmans P, Morrow M, et al. Breast cancer[J]. Lancet, 2021, 397(10286)：1750-1769.
|
| [21] |
Thike AA, Cheok PY, Jara-Lazaro AR, et al. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer[J]. Mod Pathol, 2010, 23(1)：123-133.
|
| [22] |
Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results Database[J]. Cancer, 2007, 110(4)：876-884.
|
| [23] |
Bao P, Peng P, Gu K, et al. Long-term survival analysis of different breast cancer molecular subtypes: Shanghai breast cancer survival study[J]. Zhonghua Wai Ke Za Zhi, 2015, 53(12)：928-934.
|
| [24] |
Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry[J]. Cancer, 2007, 109：1721-1728.
|
| [25] |
Rauh C, Gass P, Heusinger K, et al. Association of molecular subtypes with breast cancer risk factors: a case-only analysis[J]. Eur J Cancer Prev, 2015, 24(6)：484-490.
|
| [26] |
Yuan Y, Pan K, Mortimer J, et al. Metabolic syndrome risk components and mortality after triple-negative breast cancer diagnosis in postmenopausal women in the Women’s Health Initiative[J]. Cancer, 2021, 127(10)：1658-1667.
|
| [27] |
Harborg S, Zachariae R, Olsen J, et al. Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis[J]. NPJ Breast Cancer, 2021, 7(1)：119.
|
| [28] |
Gourgue F, Mignion L, Van Hul M, et al. Obesity and triple-negative-breast-cancer: is apelin a new key target？[J]. J Cell Mol Med, 2020, 24(17)：10233-10244.
|
| [29] |
Mejri N, El Benna H, Rachdi H, et al. Reproductive risk factors of inflammatory breast cancer according to luminal, HER-2-overexpressing, and triple-negative subtypes: a case comparison study[J]. Oncol Res Treat, 2020, 43(5)：204-210.
|
| [30] |
Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple negative breast cancer[J]. J Natl Cancer Inst, 2011, 103(6)：470-477.
|
| [31] |
Dolle JM, Daling JR, White E, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18 (4)：1157-1166.
|
| [32] |
Lorona NC, Cook LS, Tang MC, et al. Recent use of oral contraceptives and risk of luminal B, triple-negative, and HER2-overexpressing breast cancer[J]. Horm Cancer, 2019, 10(2-3)：71-76.
|
| [33] |
Kabat GC, Kim M, Phipps AI, et al. Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women[J]. Cancer Causes Control, 2011, 22(5)：775-783.
|
| [34] |
Schmidt G, Schneider C, Gerlinger C, et al. Impact of body mass index, smoking habit, alcohol consumption, physical activity and parity on disease course of women with triple-negative breast cancer[J]. Arch Gynecol Obstet, 2020, 301(2)：603-609.
|
| [35] |
Karbasian N, Sohrabi S, Omofoye TS, et al. Imaging features of triple negative breast cancer and the effect of BRCA mutations[J]. Curr Probl Diagn Radiol, 2021, 50(3)：303-307.
|
| [36] |
Dogan BE, Gonzalez-Angulo AM, Gilcrease M, et al. Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI[J]. AJR Am J Roentgenol, 2010, 194 (4)：1160-1166.
|
| [37] |
Lee YJ, Youn IK, Kim SH, et al. Triple-negative breast cancer: pretreatment magnetic resonance imaging features and clinicopathological factors associated with recurrence[J]. Magn Reson Imaging, 2020, 66：36-41.
|
| [38] |
Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings[J]. Radiology, 2009, 250 (3)：638-647.
|
| [39] |
Lev S. Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis[J]. Biochem Soc Trans, 2020, 48(2)：657-665.
|
| [40] |
Zhu X, Chen L, Huang B, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer[J]. Sci Rep, 2020, 10(1)：225.
|
| [41] |
Lee JS, Yost SE, Yuan Y. Neoadjuvant treatment for triple negative breast cancer: recent progresses and challenges[J]. Cancers (Basel), 2020, 12(6)：1404.
|
| [42] |
Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2015, 16 (4): 436.
|
| [43] |
Eikesdal HP, Yndestad S, Elzawahry A, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer[J]. Ann Oncol, 2021, 32(2)：240-249.
|
| [44] |
Kalinsky K, Diamond JR, Vahdat LT, et al. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial[J]. Ann Oncol, 2020, 31(12)：1709-1718.
|
| [45] |
Son S, Shin S, Rao NV, et al. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy[J]. Int J Biol Macromol, 2018, 110：406-415.
|
| [46] |
Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16)：1529-1541.
|
| [47] |
Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3)：405-411.
|
| [48] |
Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3)：397-404.
|